SMC Laboratories, Inc.

#CRO #fibrosis #MASH #kidney #lung #Liver. Instagram: Linkedin:

[SMC Laboratories, Inc. @SMClab2014]

We have made the English version of the #webinar we co-hosted with #JacksonLaboratoryJapan on April 17th #available.
Link ：https://t.co/ONOAshDQp2

[SMC Laboratories, Inc. @SMClab2014]

Phase III LITESPARK-022: Pembrolizumab + belzutifan significantly improved DFS vs pembrolizumab alone in high-risk ccRCC after nephrectomy.Learn More:https://t.co/TBDFqCLUDV

[SMC Laboratories, Inc. @SMClab2014]

高リスク淡明細胞型腎細胞がん患者を対象とした第III相試験（LITESPARK-022）で、術後補助療法としてペムブロリズマブ＋ベルズチファン併用療法は、ペムブロリズマブ単独療法と比較して無病生存期間（DFS）を有意に改善した。詳しくは：https://t.co/wL8nQk2dr5

[SMC Laboratories, Inc. @SMClab2014]

A New Treatment Strategy for Stage IV Lung-Limited NSCLC?
Lung transplantation achieved a 100% 1-year OS rate in patients with treatment-resistant, lung-limited NSCLC.
Learn more:https://t.co/zbcEhGOkmK

[SMC Laboratories, Inc. @SMClab2014]

クラウンバイオジャパン × SMCラボラトリーズ 共催
STAM™ × PDX × PDOでつなぐトランスレーショナル創薬の新たなアプローチ
• 日時：2026年8月6日（木）16:00～17:00（JST）
https://t.co/23nCOV8Uyi

[日本臨床腫瘍学会（JSMO） @JSMO_official]

【2026年度専門医新規・更新申請書類 提出期日を延期しました】

このたびの熊本地震の影響により郵便物の配送に遅延が発生していることを受け、専門医資格新規・更新申請書類の提出期日を下記のとおり延期いたします。

　書類提出期日：8月10日（月）消印有効　　

何卒よろしくお願い申しあげます。　　　　　　　　　　　

#JSMO #がん薬物療法専門医

[SMC Laboratories, Inc. @SMClab2014]

Stage IV肺限局型NSCLCに新たな治療戦略？
内科的治療に抵抗性を示す肺限局型NSCLC患者を対象とした研究で、肺移植群の1年OS率は100％。肺移植が新たな選択肢となる可能性が示された。詳しくは：https://t.co/ULIQchpktx

[SMC Laboratories, Inc. @SMClab2014]

Webinar on CKD Drug Discovery
Date (Rebroadcast):
July 30th, 6:30-7:00 pm JST
July 30th, 11:30–12:00 pm CEST
Title: Kidney Disease Drug Discovery: Model Selection & Study Design
https://t.co/5gjtnYKYs5
#CKD #Kidney #Discovery #StudyDesign #disease

[Sam Tsimikas, MD @Lpa_Doc]

Our latest paper: Direct measurement of Lp(a)-cholesterol (Lp(a)-C) (Developed in our lab at UCSD) shows that commonly used formula-based approaches systematically overestimate Lp(a)-C and therefore underestimate true LDL-C.
In some individuals with very high Lp(a), formula-derived corrections can even produce biologically impossible negative LDL-C values, highlighting the limitations of these estimation methods.
Our study demonstrates that empirical direct measurement of Lp(a)-C provides a more accurate assessment of LDL-C than current correction formulas.
Why does this matter clinically? Lp(a)-C can contribute 15–30 mg/dL (or more) of the cholesterol currently reported as "LDL-C." As Lp(a)-lowering therapies become available, knowing the patient's true LDL-C will become increasingly important for optimizing lipid-lowering therapy and determining whether additional LDL-C reduction is needed.
Direct Lp(a)-C measurement is now available for research through Medpace.

https://t.co/wzSCSbCDOM

[Thomas Reiberger @ReibergerThomas]

Dr. Thomas #SorzNechay of @MedUni_Wien studied #aSMA & #CD34 histomorphometry on #liverbiopsy

💡CD34 indicates #sinusoidal #capillarization
➡️expect higher #portalpressure
🩸circulating #vWF & #ELF also indicate #capillarization

@hepinternation1 🔗 https://t.co/OXaKDYHekD

[Ahmed Bennis MD 🫀 @drbennisahmed]

Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis

Cardio- and renoprotective effects expand SGLT2 inhibitor use beyond diabetes.

This review highlights SGLT2 inhibitors in aortic stenosis and pressure overload.

@JACCJournals
https://t.co/bc2fb9s2ZT

[AASLD @AASLDtweets]

⏰ Three days left!

The deadline to submit 2027 AASLD Committee & SIG nominations is Thursday, July 30.

Find the volunteer role that best matches your skills and expertise. Submit your self-nomination or nominate a colleague today.

👉 Nominate here: https://t.co/XSsRQbgDhr

[Cristina Tejera @cristinatejerap]

Dos mujeres. Mismo HbA1c, misma edad, mismo HOMA2. Se diferencian en 0,5 kg/m² de IMC.

El algoritmo asigna a una MARD y a la otra MOD.

Ese es el problema de fondo que plantea esta revisión en @DiabetologiaJnl sobre los subtipos de DM2 ➡️clasificamos sobre variables continuas y perdemos información por el camino.

No es un alegato contra los subtipos sino a favor de reportar la incertidumbre de clasificación y de usar modelos predictivos cuando lo que buscamos es decidir sobre opciones de tratamiento. Muy interesante

🔗 https://t.co/WkuSj2gtjA

[Dr Alo, DO, FACC @MohammedAlo]

Triglycerides & Residual ASCVD Risk

•⁠ ⁠A new review highlights remnant lipoproteins as a major driver of residual ASCVD risk.

•⁠ ⁠Triglycerides are a marker, not the direct cause of atherosclerosis.

•⁠ ⁠Residual risk remains high despite achieving LDL-C targets.

•⁠ ⁠ApoC-III and ANGPTL3 therapies may better reduce remnant lipoproteins.

•⁠ ⁠Conclusion: Targeting ApoB-containing remnant particles may further reduce cardiovascular risk beyond LDL-C lowering.

https://t.co/hBA24UhvtK

@DrNadolsky @DrKarlNadolsky @NutritionMadeS3 @drmatthewnagra @MichaelAlbertMD @maciejbanach

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Linvoseltamab may retain binding to cells w/ BCMA R27P S30del mutations, and demonstrated Jurkat-NFAT reporter and primary T-cell activation, as well as targeted cytotoxicity against mutated BCMA comparable to WT BCMA: https://t.co/ABrWbXM3pu. #mmsm

[SMC Laboratories, Inc. @SMClab2014]

ウェビナーにご参加いただきありがとうございます。
８月はCrown Bioscienceとの共催ウェビナーを開催いたします。みなさまのご参加お待ちしております。
#九道 #ウェビナー #嚢胞 ＃腎臓 ＃Thankyou

[SMC Laboratories, Inc. @SMClab2014]

創薬モデル、どう選ぶ？STAM™・PDX・PDOを統合した次世代トランスレーショナル評価戦略を解説。研究の再現性向上から試験設計の最適化まで、Crown Bioscience Japan×SMCラボラトリーズが共催。
📅8/6(木) 16:00–17:00（JST）【参加無料】
🔗https://t.co/23nCOV8Uyi

[AASLD @AASLDtweets]

Learn on-the-go as we collaborate with ISDA, ALEH, and API during a webinar on Viral Hepatitis in Latin America on World Hepatitis Day at 7 p.m. EDT! Held in Spanish with English subtitles, join AASLD/IDSA member Harrys Torres, MD, FAASLD, and ALEH member Ezequiel Ridruejo, MD, PhD as they discuss #hepatitisC and #hepatitisB.  

Prepare for the in-depth conversation on vaccination, diagnosis, and treatment approaches that lead to a roundtable on current efforts of viral hepatitis elimination. Register now at  https://t.co/T8KPAKhnOQ.

[AASLD Foundation @AASLDFoundation]

Congratulations to Enis Kostallari, PhD, MS, on receiving the 2026 Pilot Research Award in Liver Diseases for the project: Cilia-mediated nucleotide metabolism in hepatic stellate cells promotes liver fibrosis 🎉

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Cellular therapy in mantle cell #lymphoma: recommendations from the @TheEBMT practice harmonisation and guidelines committee #lymsm #bmtsm #CARTcell https://t.co/EwcBNTjiGY

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy - @EUplatinum @OncoAlert @urotoday #cCR @IBCG_BladderCA #Milancriteria @SanRaffaeleMI @MyUniSR https://t.co/1hFuIT0QK4